Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

CovaRisk: Validating a Digital Tool for Ovarian Cancer Risk Assessment and Referral (CovaRisk)

10. november 2026 oppdatert av: Ahmed Kamal Eldin Abbas Attia, Benha University

Bridging Diagnosis and Decision-Making: Retrospective Validation of CovaRisk for Ovarian Malignancy Risk Stratification and Referral Triage

Ovarian cancer is frequently diagnosed at an advanced stage, while its early symptoms are often nonspecific . In women presenting with an adnexal mass, clinicians must integrate clinical symptoms, menopausal status, tumour markers, ultrasound findings, cross-sectional imaging, and hereditary risk when deciding whether a patient requires urgent gynaecologic oncology referral, specialist review, additional imaging, or conservative follow-up . Existing validated tools address individual components of this pathway, but these tools and guideline recommendations are distributed across different resources .

Studieoversikt

Detaljert beskrivelse

CovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment . It combines symptom criteria, age-adjusted CA-125 interpretation, HE4/ROMA, Risk of Malignancy Index (RMI), IOTA Simple Rules, O-RADS ultrasound and MRI classification, selected tumour markers, and hereditary risk information. The tool provides a transparent triage category and guideline-based next steps while directing users to established specialist tools where appropriate. CovaRisk is intended to support, rather than replace, clinical judgement and validated specialist models .This study aims to evaluate the diagnostic accuracy of CovaRisk version 1.0 for identifying ovarian malignancy, including borderline tumours, using final histopathology as the reference standard, and to compare its performance with the Risk of Malignancy Index and O-RADS ultrasound classification in the same cohort .This study will be a single-centre retrospective diagnostic accuracy study of women aged 18 years or older who underwent surgery for an adnexal mass and have final histopathology available. Preoperative information will be entered into the frozen CovaRisk version 1.0 without access to the postoperative histopathology result . CovaRisk classification will be compared with final histology as the reference standard. Diagnostic performance will be assessed using sensitivity, specificity, predictive values, likelihood ratios, receiver operating characteristic curves and area under the curve . CovaRisk will also be compared with RMI and O-RADS ultrasound in the same cohort .The study will provide an objective assessment of whether CovaRisk can accurately identify ovarian malignancy in a real-world hospital population. The findings will guide refinement of the tool and determine whether it is appropriate to proceed to subsequent usability testing and prospective validation.Innovation CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterisation of adnexal masses , standardised imaging risk stratification, and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population.

In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide. These features are consistent with the recognised role of clinical decision support systems in standardising care and reducing unwarranted variation in clinical decision-making .

Studietype

Observasjonsmessig

Registrering (Antatt)

320

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Women aged 18 years or older who underwent surgery for an adnexal mass at King Faisal Specialist Hospital & Research Centre, Madinah, Saudi Arabia, between January 2021 and December 2025, and who have final histopathology available. Consecutive eligible cases are identified from operating theatre records and the institutional histopathology database. Included records contain sufficient preoperative information, at least a preoperative ultrasound report or a CA-125 result. Women with previous ovarian cancer are excluded. Data are extracted retrospectively from existing medical records; no participants are recruited or contacted.

Beskrivelse

Inclusion Criteria:

  • Women aged 18 years or older.
  • Surgical treatment for an adnexal mass at the host institution during the defined retrospective study period.
  • Availability of final histopathology.
  • Availability of sufficient preoperative clinical information, including at least a preoperative ultrasound report and CA-125 result, according to the study eligibility definition

Exclusion Criteria:

  • Previous ovarian cancer.

    • Absence of both a preoperative ultrasound report and CA-125 result.
    • Records in which the relevant preoperative information cannot be reliably established.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Retrospective Adnexal Mass Diagnostic Cohort

A single retrospective cohort of women aged 18 years or older who underwent surgical treatment for an adnexal mass at King Faisal Specialist Hospital & Research Centre, Madinah. Preoperative clinical, laboratory, imaging, and hereditary risk data are entered into the CovaRisk version 1.0 tool (blinded to final outcomes), and its diagnostic performance is evaluated against final histopathology as the reference standard, alongside comparative assessments using the Risk of Malignancy Index (RMI) and O-RADS ultrasound classification

CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterization of adnexal masses , standardized imaging risk stratification , and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population.

In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide.

Andre navn:
  • CovaRisk
  • TOOL
Arm 1: CovaRisk - Diagnostic classification using the CovaRisk version 1.0 tool. Arm 2: Risk of M

This is a retrospective diagnostic accuracy study. These are paired diagnostic assessment methods applied to the same patients, not separate groups receiving different interventions.

CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterization of adnexal masses , standardized imaging risk stratification , and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population.

In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide.

Andre navn:
  • CovaRisk
  • TOOL

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sensitivity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy, Including Borderline Tumors, Against Final Histopathology
Tidsramme: Single retrospective record review of surgeries performed January 2021 to December 2025

Proportion of women with a histologically confirmed malignant or borderline ovarian tumour who are classified as high-risk by CovaRisk v1.0. CovaRisk is applied to preoperative data already recorded in medical records, without knowledge of the histopathology result. Reported as a percentage with 95% confidence interval.

Single retrospective record review of surgeries performed January 2021 to December 2025
Specificity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy Against Final Histopathology
Tidsramme: Single retrospective record review of surgeries performed January 2021 to December 2025

•Proportion of women with benign final histopathology who are classified as not high-risk (intermediate, low or information-only) by CovaRisk v1.0. Reported as a percentage with 95% confidence interval.

Single retrospective record review of surgeries performed January 2021 to December 2025

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Positive Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy
Tidsramme: Single retrospective record review of surgeries performed January 2021 to December 2025.

Proportion of women classified as high-risk by CovaRisk v1.0 who have malignant or borderline final histopathology, with 95% confidence interval.

Unit: percentage of participants

Single retrospective record review of surgeries performed January 2021 to December 2025.
Negative Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy
Tidsramme: Single retrospective record review of surgeries performed January 2021 to December 2025

Proportion of women not classified as high-risk by CovaRisk v1.0 who have benign final histopathology, with 95% confidence interval.

Unit: percentage of participants

Single retrospective record review of surgeries performed January 2021 to December 2025

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. januar 2028

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

11. oktober 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

The document primarily notes that research data will be stored securely on password-protected institutional systems and accessible only to authorized members of the research team in compliance with data-protection requirements.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere